Managing Cancer-Related Nerve Pain: Where Pharmacist Follow-Up Fits

Neuropathic pain management requires decisions that extend beyond the initial prescription. A retrospective Japanese study examining pharmacist-supported mirogabalin treatment offers a preliminary signal of benefit, while illustrating the difficulty of measuring the contribution of pharmacy care.¹

For oncology pharmacists, the practical question is how to structure follow-up around the cause of pain and the patient’s response. A medication recommendation creates an opportunity to establish what improvement should look like, then revisit whether treatment is meeting that goal.

A Promising Association With Important Limits

Kajiura and colleagues included 85 adults with malignancy, of whom 18 received pharmacist-led recommendation and management, and 67 received prescribing without pharmacist recommendation. Among evaluable records, documented subjective improvement occurred in 13 of 13 patients versus 36 of 52 (69.2%; P = .027).¹

When unevaluable records were retained in a conservative sensitivity analysis, rates were 72.2% versus 53.7%, and the difference was not statistically significant (P = .188). Discontinuation because of adverse events also did not differ significantly: 5.6% versus 11.9% (P = .677). These findings are hypothesis-generating, as the nonrandomized design and missing records limit interpretation.¹

Identify the Pain Before Selecting Treatment

Cancer-related neuropathic pain includes more than chemotherapy-induced peripheral neuropathy (CIPN). Tumor involvement of nerves and treatment-related nerve injury can produce different clinical presentations. The National Cancer Institute (NCI) emphasizes characterizing pain and its underlying cause before selecting therapy.²

That distinction changes how the evidence should be applied. In its 2020 CIPN guideline update, ASCO identified duloxetine as the only agent with appropriate evidence for established painful CIPN, while acknowledging limited benefit. The guideline also recommends considering chemotherapy modification when neuropathy becomes intolerable or impairs function.³

A pharmacist reviewing persistent symptoms can therefore help the oncology team distinguish an inadequate analgesic response from toxicity that warrants reassessment of anticancer treatment. Continuing to add symptom medications without revisiting the source of pain risks overlooking the decision that matters most.

Mirogabalin’s regulatory context also requires attention. Daiichi Sankyo reported that Japan expanded Tarlige’s indication from peripheral neuropathic pain to neuropathic pain in 2022. That Japanese approval does not establish a US indication or make the retrospective findings a basis for routine substitution in CIPN care.⁴

Make Safety Part of Every Reassessment

Follow-up should examine tolerability alongside reported relief. The FDA warns that gabapentin and pregabalin can cause serious breathing difficulties in patients with respiratory risk factors, including concurrent opioid use. Older adults and patients who have impaired lung function are also at greater risk.⁵

When these agents are prescribed with opioids or other central nervous system depressants, the FDA recommends starting at the lowest dose and monitoring for sedation and respiratory depression. Counseling should explain when excessive sleepiness or slowed breathing requires immediate medical attention.⁵

For pharmacy practice, this supports reviewing the full medication list whenever an analgesic is initiated or increased. A patient who reports less pain but becomes difficult to awaken needs urgent assessment; the lower pain score alone does not establish an acceptable treatment response.

Give Follow-Up a Defined Purpose

The NCI recommends longitudinal monitoring to adjust treatment and assess its effects on function.² Pharmacists can translate that approach into a documented follow-up plan by establishish a baseline pain rating and a patient-selected activity, then compare subsequent reports with the starting point.

For example, asking whether a patient can walk to the bathroom more comfortably gives the next conversation a concrete reference. Recording why treatment was changed also helps the next health care professional understand whether the concern was insufficient relief or poor tolerability.

This is a practical application of established assessment principles, rather than a protocol validated by the mirogabalin study. A useful pharmacy encounter ends with a documented response and a clear next step, so persistent symptoms prompt reassessment instead of an automatic refill.

REFERENCES

1. Kajiura S, Ishikawa Y, Kato A, Hayashi R. Cancer Patients with Neuropathic Pain: Pharmacist-Led Recommendation and Management and Mirogabalin Outcomes in a Single-Center Retrospective Observational Cohort. J Pain Palliat Care Pharmacother. 2026;40(3):425-432. doi:10.1080/15360288.2026.2684413

2. National Cancer Institute. Cancer pain (PDQ®)–health professional version. Accessed October 22, 2026. https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq

3. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399

4. Daiichi Sankyo. Tarlige tablets approved in Japan for treatment of patients with neuropathic pain. March 28, 2022. Accessed October 22, 2026. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202203/20220328_E.pdf

5. US Food and Drug Administration. Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): drug safety communication—serious breathing problems. December 19, 2019. Accessed October 22, 2026. https://www.fda.gov/safety/medical-product-safety-information/neurontin-gralise-horizant-gabapentin-and-lyrica-lyrica-cr-pregabalin-drug-safety-communication